Marie Foegh, MD, DrSc, has accepted the position as CEO of 2X Oncology Inc. an OV spinout
Hoersholm, Denmark, January 3rd, 2017 – Oncology Venture Sweden AB (OV.ST) today announced that Marie Foegh, MD, DrSc, has been appointed and has accepted the position as CEO of 2X Oncology Inc. (2XO). 2XO is a Women’s Cancer precision medicine company focused on advancing the development of promising, novel clinical-stage cancer drugs – in combination with the Drug Response Predictor (DRP™), a platform technology that develops companion diagnostics to select high likelihood responding patients. Dr. Foegh has 28 years of global experience in the pharmaceutical and biotechnology industries in